Literature DB >> 3853963

In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus.

S Alvarez, M Jones, S L Berk.   

Abstract

We tested 148 strains of clinical isolates of methicillin-resistant Staphylococcus aureus against fosfomycin alone and in combination with methicillin, cefamandole, gentamicin, trimethoprim, and vancomycin. Fosfomycin inhibited 90% of the 148 methicillin-resistant S. aureus strains at a concentration of 4 micrograms/ml. Synergism was observed in 97 strains (66%) with fosfomycin-cefamandole and in 69 strains (46%) with fosfomycin-methicillin. The combinations of fosfomycin with vancomycin, gentamicin, and trimethoprim were indifferent in most strains.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3853963      PMCID： PMC176358          DOI： 10.1128/AAC.28.5.689

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Bacteriological evaluation of fosfomycin in clinical studies.

Authors:  A Rodríguez; A Gallego; T Olay; J M Mata
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

2.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

3.  International recognition of methicillin-resistant strains of Staphylococcus aureus.

Authors:  R L Thompson; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

4.  [Comparison of activity of fosfomycin, oxacillin and penicillin G against staphylococci and micrococci (author's transl)].

Authors:  G Peters; F Schumacher-Perdreau; G Pulverer
Journal:  Dtsch Med Wochenschr       Date:  1980-10-31       Impact factor: 0.628

5.  Antimicrobial activity of fosfomycin in vitro.

Authors:  A Forsgren; M Walder
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

6.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci.

Authors:  C Thornsberry; L K McDougal
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

9.  Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus.

Authors:  D E Craven; N R Kollisch; C R Hsieh; M G Connolly; W R McCabe
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691
View more
  13 in total

1.  In vitro synergistic activity between meropenem and other beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Y Sumita; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 2.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

3.  Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits.

Authors:  P Chavanet; E Muggeo; A Waldner; S Dijoux; D Caillot; H Portier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

4.  Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C Thauvin; J F Lemeland; G Humbert; J P Fillastre
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.

Authors:  A Bruce Montgomery; Shirley Vallance; Tammy Abuan; Markus Tservistas; Andrew Davies
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

7.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

8.  Nosocomial septicemias due to methicillin-resistant staphylococcus aureus and Pseudomonas aeruginosa in a university hospital over a 12-year period--the same intractable infections.

Authors:  Y Mizushima; H Li; I Yoshida; K Sassa; T Hamazaki; M Kobayashi
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

9.  The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci.

Authors:  S Gatermann; E Schulz; R Marre
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

10.  Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.

Authors:  Y Utsui; S Ohya; T Magaribuchi; M Tajima; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.